Intravital Dynamic and Correlative Imaging of Mouse Livers Reveals Diffusion‐Dominated Canalicular and Flow‐Augmented Ductular Bile Flux

Nachiket Vartak, Georgia Guenther, Florian Joly, Amruta Damle‐Vartak, Gudrun Wibbelt, Jörns Fickel, Simone Jörs, Brigitte Begher‐Tibbe, Adrian Friebel, Kasimir Wansing, Ahmed Ghallab, Marie Rosselin, Noemie Boissier, Irene Vignon‐Clementel, Christian Hedberg, Fabian Geisler, Heribert Hofer, Peter Jansen, Stefan Hoehme, Dirk Drasdo, Jan G. Hengstler – 19 June 2020

APECED‐Associated Hepatitis: Clinical, Biochemical, Histological and Treatment Data From a Large, Predominantly American Cohort

David M. Chascsa, Elise M. N. Ferré, Yannis Hadjiyannis, Hawwa Alao, Mukil Natarajan, Mariam Quinones, David E. Kleiner, Thomas L. Simcox, Ehsan Chitsaz, Stacey R. Rose, Asa Hallgren, Olle Kampe, Jamie Marko, Rabab O. Ali, Sungyoung Auh, Christopher Koh, Yasmine Belkaid, Michail S. Lionakis, Theo Heller – 17 June 2020

Liver X Receptor Alpha Activation Inhibits Autophagy and Lipophagy in Hepatocytes by Dysregulating Autophagy‐Related 4B Cysteine Peptidase and Rab‐8B, Reducing Mitochondrial Fuel Oxidation

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma

Won‐Mook Choi, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Young‐Suk Lim, Han Chu Lee, Young‐Hwa Chung, Young‐Sang Lee, Sook Ryun Park, Min‐Hee Ryu, Baek‐Yeol Ryoo, So Jung Lee, Kang Mo Kim – 16 June 2020 – Regorafenib and nivolumab are drugs approved for second‐line treatment of patients with hepatocellular carcinoma (HCC) after sorafenib failure. However, the effectiveness of regorafenib and nivolumab following sorafenib has not been directly compared.

From NAFLD to MAFLD: Implications of a Premature Change in Terminology

Zobair M. Younossi, Mary E. Rinella, Arun J. Sanyal, Stephen A. Harrison, Elizabeth M. Brunt, Zachary Goodman, David E. Cohen, Rohit Loomba – 16 June 2020 – Despite the substantial gains in our understanding of NAFLD/NASH over the past 2 decades, there has been some dissatisfaction with the terminology “non‐alcoholic” which overemphasizes “alcohol” and underemphasizes the root cause of this liver disease, namely, the predisposing metabolic risk factors. As a potential remedy, a name change from NAFLD to metabolic associated fatty liver disease (MAFLD) has been proposed.

Association of Perfusion Characteristics and Posttransplant Liver Function in Ischemia‐Free Liver Transplantation

Zhiheng Zhang, Yunhua Tang, Qiang Zhao, Linhe Wang, Caihui Zhu, Weiqiang Ju, Dongping Wang, Lu Yang, Linwei Wu, Maogen Chen, Shanzhou Huang, Ningxin Gao, Zebin Zhu, Yixi Zhang, Chengjun Sun, Wei Xiong, Yuekun Shen, Yi Ma, Anbin Hu, Xiaofeng Zhu, Jian Rong, Changjie Cai, Zhiyong Guo, Xiaoshun He – 15 June 2020 – It has been shown that normothermic machine perfusion (NMP), a novel preservation method, is able to assess and resuscitate liver grafts with risk factors. However, there is no consistent criteria for the assessment of liver grafts with NMP.

Subscribe to